All In Biotech

Free tool

FAERS Monitor: Miebo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216675 or its brand name (Miebo, Perfluorohexyloctane). Reports on generic versions are filed under their own applications.

Reports

2,325

Serious

761

33% of reports

Hospitalization

210

Death reported

166

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • inappropriate schedule of product administration328
  • eye pain307
  • eye irritation297
  • vision blurred275
  • product use issue240
  • product delivery mechanism issue201
  • drug ineffective177
  • circumstance or information capable of leading to medication error170
  • product use complaint164
  • ocular hyperaemia159
  • death158
  • dry eye154
  • accidental exposure to product134
  • exposure via skin contact133
  • headache124

Reports by year received

View as table
YearReports
20213
202210
202366
2024398
2025926
2026922

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,834 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product delivery mechanism issueSignal201351.3306.967,264
product use complaintSignal16495.282.015,038
eye painSignal30749.544.614,496
eye irritationSignal29746.942.213,268
exposure via skin contactSignal13346.739.55,874
circumstance or information capable of leading to medication errorSignal17045.839.67,372
ocular hyperaemiaSignal15930.426.24,488
dry eyeSignal15428.024.03,979
vision blurredSignal27518.216.24,460
inappropriate schedule of product administrationSignal32816.514.94,790
accidental exposure to productSignal13411.810.01,315
product use issueSignal24011.610.32,324
headache1241.81.544
death1581.71.442
drug ineffective1771.21.17

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.